Protagonist Therapeutics, Inc (PTGX) stock
PTGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 12/30199% above fair value
$124.67−0.16 (-0.13%)
Close on Nov 17, 2026Market cap $8.07BP/E 121.0Yield –
Protagonist Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Protagonist Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $175.16M, up 21.8% year over year. For fiscal 2025 it was $159.29M, up 15.3% from the year before. Over ten years it grew 29.7% a year on average. The highest annual figure on record is $159.29M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $159.29M | +15.3% |
| FY2024 | Dec 31, 2024 | $138.13M | +15.0% |
| FY2023 | Dec 31, 2023 | $120.16M | -4.8% |
| FY2022 | Dec 31, 2022 | $126.22M | +0.2% |
| FY2021 | Dec 31, 2021 | $126.01M | +69.1% |
| FY2020 | Dec 31, 2020 | $74.51M | +14.6% |
| FY2019 | Dec 31, 2019 | $65.00M | +9.3% |
| FY2018 | Dec 31, 2018 | $59.50M | +28.8% |
| FY2017 | Dec 31, 2017 | $46.18M | +79.7% |
| FY2016 | Dec 31, 2016 | $25.71M | +117.3% |
| FY2015 | Dec 31, 2015 | $11.83M | +58.6% |
| FY2014 | Dec 31, 2014 | $7.46M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $42.06M | +13.6% |
| Q1 FY2026 | Mar 31, 2026 | $46.74M | +30.2% |
| Q4 FY2025 | Dec 31, 2025 | $46.36M | +32.8% |
| Q3 FY2025 | Sep 30, 2025 | $40.00M | +11.2% |
| Q2 FY2025 | Jun 30, 2025 | $37.04M | +10.5% |
| Q1 FY2025 | Mar 31, 2025 | $35.89M | +6.4% |
| Q4 FY2024 | Dec 31, 2024 | $34.90M | +20.8% |
| Q3 FY2024 | Sep 30, 2024 | $35.97M | +17.3% |
| Q2 FY2024 | Jun 30, 2024 | $33.52M | +1.0% |
| Q1 FY2024 | Mar 31, 2024 | $33.73M | +23.0% |
| Q4 FY2023 | Dec 31, 2023 | $28.90M | -3.3% |
| Q3 FY2023 | Sep 30, 2023 | $30.66M | +20.7% |
| Q2 FY2023 | Jun 30, 2023 | $33.18M | -4.1% |
| Q1 FY2023 | Mar 31, 2023 | $27.42M | -24.5% |
| Q4 FY2022 | Dec 31, 2022 | $29.88M | -22.1% |
| Q3 FY2022 | Sep 30, 2022 | $25.40M | -31.3% |
| Q2 FY2022 | Jun 30, 2022 | $34.61M | +30.9% |
| Q1 FY2022 | Mar 31, 2022 | $36.32M | +49.8% |
| Q4 FY2021 | Dec 31, 2021 | $38.37M | +96.9% |
| Q3 FY2021 | Sep 30, 2021 | $36.96M | +131.0% |
| Q2 FY2021 | Jun 30, 2021 | $26.43M | +30.5% |
| Q1 FY2021 | Mar 31, 2021 | $24.25M | +29.2% |
| Q4 FY2020 | Dec 31, 2020 | $19.49M | +22.5% |
| Q3 FY2020 | Sep 30, 2020 | $16.00M | -7.5% |
| Q2 FY2020 | Jun 30, 2020 | $20.26M | +4.7% |
| Q1 FY2020 | Mar 31, 2020 | $18.77M | +50.8% |
| Q4 FY2019 | Dec 31, 2019 | $15.91M | +11.7% |
| Q3 FY2019 | Sep 30, 2019 | $17.29M | +42.4% |
| Q2 FY2019 | Jun 30, 2019 | $19.36M | +9.1% |
| Q1 FY2019 | Mar 31, 2019 | $12.44M | -19.0% |
| Q4 FY2018 | Dec 31, 2018 | $14.25M | +21.5% |
| Q3 FY2018 | Sep 30, 2018 | $12.15M | +8.7% |
| Q2 FY2018 | Jun 30, 2018 | $17.74M | +47.7% |
| Q1 FY2018 | Mar 31, 2018 | $15.37M | +36.2% |
| Q4 FY2017 | Dec 31, 2017 | $11.72M | +32.9% |
| Q3 FY2017 | Sep 30, 2017 | $11.17M | +100.8% |
| Q2 FY2017 | Jun 30, 2017 | $12.01M | – |
| Q1 FY2017 | Mar 31, 2017 | $11.28M | – |
| Q4 FY2016 | Dec 31, 2016 | $8.82M | – |
| Q3 FY2016 | Sep 30, 2016 | $5.56M | – |
See a number that looks wrong?